The federal Project Grant award in the amount of $640,000.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to The Cleveland Clinic Foundation. The award, with a start date of September 1, 2024 and an ultimate completion date of August 31, 2026, will fund evolutionary experimentation research to identify novel therapeutic vulnerabilities in endometrial cancer. As a leading academic medical center and research institution, The Cleveland Clinic Foundation will leverage its expertise in cancer biology, genetics, and immunology to conduct the innovative biomedical research supported by this grant. The award represents the Foundation's continued partnership with federal agencies like the Department of Defense, National Institutes of Health, and Centers for Disease Control and Prevention in driving advancements in medical solutions for critical health challenges.
Generated 3/25/25, 4:00 AM